Loading publications…
The last 5 uploaded publications
Data from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison (2023). Data from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. , DOI: https://doi.org/10.1158/2159-8290.c.6548299.
Preprint62 days agoSupplementary Methods from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison, Amit Khot, Natalie Brajanovski (2023). Supplementary Methods from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. , DOI: https://doi.org/10.1158/2159-8290.22537003.
Preprint62 days agoData from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison (2023). Data from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. , DOI: https://doi.org/10.1158/2159-8290.c.6548299.v1.
Preprint62 days agoSupplementary Figure S2 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison (2023). Supplementary Figure S2 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. , DOI: https://doi.org/10.1158/2159-8290.22537012.
Preprint62 days agoSupplementary Figure S3 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison (2023). Supplementary Figure S3 from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. , DOI: https://doi.org/10.1158/2159-8290.22537006.
Preprint62 days ago